The patients Omer describes did not arrive willingly. They came reluctantly, defiantly, exhausted, and they came anyway. That paradox, the simultaneous resistance to and hunger for clinical conversation, sits at the heart of what the essay argues makes psychiatric communication unlike anything else in medicine. A cardiologist can lean on imaging and lab values; a psychiatrist has only language, silence, and presence. The discipline asks its practitioners to enter a reality that may be foreign, frightening, or, in the most unsettling cases, uncomfortably familiar. Omer invokes Atticus Finch’s advice to his daughter in To Kill a Mockingbird, that you never really understand a person until you climb inside his skin and walk around in it, as a description of the task psychiatry sets, and then immediately notes how much harder the task becomes once you actually attempt it.

The essay’s central case is a 16-year-old girl met early in the author’s clinical experience, sitting in an emergency department with her arms crossed so tightly that the posture read less as defiance than as an effort to hold herself together. Her story emerged in fragments: grades slipping, a friend group that had closed like a door, and what Omer calls the private arithmetic of never being enough. What made the encounter clinically instructive, and personally destabilizing, was recognition. The student felt the floor tilt because the arithmetic was familiar: the sense of doing everything possible and watching it fail anyway, the certainty of disappointing everyone. For a moment, the essay admits, it was impossible to tell where the patient ended and the trainee began.

That blurring, Omer argues, is the danger nobody warns students about. The essay reaches for Emily Brontë to name it, quoting Catherine’s declaration about Heathcliff in Wuthering Heights, “He’s more myself than I am,” as the temptation facing every young clinician: the belief that the truest form of empathy is to disappear into another person’s experience. But the patient’s pain was hers, not a costume to be tried on, and treating it as one’s own would have meant, in effect, stopping the work of listening to her. The essay grounds this intuition in the clinical literature, citing a 2024 narrative review of empathy in the work of clinical psychiatrists published in BJPsych Advances, which frames empathy not as feeling what the patient feels but as a disciplined effort to understand the patient’s experience while keeping the boundary between clinician and patient intact. Empathy done well, in this account, is not a merging of selves but an ethical act of imagination. The job is not to recognize yourself in the patient. It is to recognize the patient.

If empathy can pull a clinician too close, the essay’s second movement argues, fear pulls too far. Omer describes sitting on an inpatient unit with a man with schizophrenia who talked about his auditory hallucinations the way one might describe weather or difficult neighbors: constant, opinionated, occasionally cruel. The voices warned him about strangers. They narrated him back to himself. From a clinical distance, such experiences get filed under “unreal” and the conversation moves on. Up close, the voices furnished his world as solidly as the furniture in the room. Arguing him out of them was never the assignment, and the essay is emphatic on this point: the therapeutic move is closer to the opposite of correction.

Here, too, the reflection leans on published evidence. Omer cites a 2023 study in Psychology and Psychotherapy by Eleanor Longden and colleagues, which gathered the perspectives of service users who hear voices on therapy that engages the hallucinations directly, formulating them as meaningful experiences rather than dismissing them as symptoms to be suppressed. Patients in that work described being able, at last, to relate to their voices, and to themselves, on new terms. In the essay’s telling, the practical translation is disarmingly simple: ask what the voices say, and let the patient see that you believe he hears them. That is not endorsement of delusional content; it is acknowledgment of experience, and it is often the first genuine exchange a patient has had in some time.

The hardest communication scenario the essay takes on is fear pointed at the clinician. Omer describes an afternoon encounter with a patient pacing the hallway, throwing his voice and then his fist at the wall, while staff visibly braced. It is, the essay observes, the easiest thing in medicine to see only threat in that moment, to let a person collapse into his loudest behavior. But if a clinician can stay in the room a beat longer than adrenaline wants, the noise begins to resolve into words, and the words are usually some version of the same plea: do not leave, do not ignore me, someone please still be here. De-escalation, when it works, is mostly that.

The claim is not merely anecdotal. The essay cites a 2024 analysis published in BMC Psychiatry by Owen Price and colleagues, a behavior-change theory-informed secondary qualitative analysis of staff and patient perspectives on de-escalating aggression in acute inpatient mental health settings. The study’s conclusions, as the essay summarizes them, are strikingly unshowy: name the distress beneath the volume, close the social distance rather than the exits, and confirm the person’s sense of authority instead of stripping it away. Anger, the essay concludes, is often fear that has run out of quieter options. For a specialty frequently portrayed in popular culture as a contest of dramatic interventions, the evidence points toward skills that are almost invisible: a question asked slowly, a silence deliberately left unfilled, the decision to remain in the room when the suffering is hard to watch.

Omer reaches for George Eliot to give these small acts their proper weight, recalling the closing passage of Middlemarch in which Eliot writes that the growing good of the world depends on unhistoric acts. Psychiatry, the essay argues, is built almost entirely from such acts: the decision to listen, the willingness to sit with a perspective that unsettles you, the discipline to stay. None of it looks like television. There are no clean saves, no monologues that cure. What remains is the accumulation of moments in which a patient realizes that another person is still present, still attending, still there.

The essay closes by returning to its borrowed epigraph. Patients arrive, Omer writes, in half agony and half hope, both at once, neither giving way to the other: the girl who needed to hear that she was enough, the man at home in a world only he could hear, the patient whose threats were a last, loud argument against being left. In each case, communication became a kind of faith, the wager that understanding a person, even partway, can make that person less alone. The essay does not claim that this cures anything. Its conclusion is more modest and, arguably, more demanding: meet people where agony and hope are still fighting it out, and stay long enough that, for a moment, agony makes room for hope. As a piece of medical education scholarship, the work is a reminder that the technical core of psychiatry, empathy with boundaries, engagement with psychosis, de-escalation grounded in evidence, is inseparable from the human core, and that the learner’s voice deserves a place in the literature that trains the profession’s future.

Subject of Research: Communication, empathy, and de-escalation in clinical psychiatry

Article Title: Half Agony, Half Hope

Article References: Omer, M. (2026). Half Agony, Half Hope. Academic Psychiatry. https://doi.org/10.1007/s40596-026-02447-0

Image Credits: AI Generated

DOI: 10.1007/s40596-026-02447-0

Keywords: psychiatry, empathy, therapeutic relationship, communication, de-escalation, schizophrenia, auditory hallucinations, medical education, mental health, psychotherapy, reflective writing, adolescent mental health

Schizophrenia affects roughly one in every hundred people worldwide, and while antipsychotic medications control many of its features, a substantial fraction of patients continue to experience persistent auditory hallucinations, hearing voices that no one else can hear, as well as entrenched negative symptoms such as social withdrawal, emotional flatness, and loss of drive. These residual symptoms are among the most disabling aspects of the illness and are notoriously resistant to pharmacological escalation. This therapeutic gap has fueled decades of interest in brain stimulation techniques that might modulate the dysfunctional neural circuits thought to underlie them, offering hope for patients who have exhausted conventional options.

The technique tested in STIM’Zo belongs to a family of methods known as low-intensity transcranial electrical stimulation. Unlike transcranial magnetic stimulation, which uses rapidly changing magnetic fields to induce currents strong enough to trigger neuronal firing, transcranial electrical stimulation delivers currents so weak, typically on the order of one to two milliamps, that they do not directly cause neurons to discharge. Instead, these faint currents subtly shift the resting electrical potential of cortical neurons, nudging their excitability up or down depending on the stimulation protocol. Transcranial direct current stimulation applies a steady current, whereas tRNS delivers current that fluctuates randomly across a range of frequencies, a design intended to prevent the brain from habituating to a constant signal and to exploit the tendency of neural networks to resonate with stochastic input.

Earlier evidence for tRNS and its close cousin tDCS in schizophrenia rested on a fragile foundation of case reports and small pilot studies, some of which reported striking reductions in hallucination severity. Encouraged by these signals, the STIM’Zo investigators, led by Jerome Brunelin, Marine Mondino, and Emmanuel Poulet and their collaborators, designed a definitive test. The trial was registered as NCT02744989 and received support from the French Ministry of Health, the NeuroDis foundation, and the Centre Scientifique de Monaco, with no funder involvement in the design, analysis, or reporting of the study.

The trial’s methodology reflects the highest standard of clinical rigor. Triple-blind means that patients, the clinicians assessing outcomes, and the statisticians analyzing the data all remained unaware of who received active stimulation and who received sham. The sham condition was engineered to mimic the sensations of real stimulation, typically a brief tingling or itching at the electrode sites at the start of each session, without delivering therapeutic current. Patients were randomized across multiple centers, and the primary outcome was defined in advance as clinical response at Day 5, operationalized as a reduction of at least 25 percent on the total score of the Positive and Negative Syndrome Scale, the most widely used standardized instrument for measuring schizophrenia symptom severity. Secondary outcomes tracked symptoms at one, three, and six months using additional instruments including the Auditory Hallucinations Rating Scale, the Calgary Depression Scale for Schizophrenia, the Clinical Global Impression scale, and a schizophrenia-specific quality of life questionnaire.

The primary analysis included 132 patients, 64 in the active stimulation group and 68 in the sham group, with balanced sex distributions across arms. The result was unambiguous. At Day 5, only 6 of 64 patients in the active group, or 9.4 percent, met the response criterion, compared with 9 of 68 patients, or 13.2 percent, in the sham group. The difference between groups was not statistically significant, with an effect estimate of negative 0.38 and a 95 percent confidence interval spanning negative 1.64 to 0.89, and a p value of 0.56. In plain terms, the sham procedure performed slightly, though not significantly, better than the real intervention. None of the secondary outcomes, measured over the following six months, showed significant differences either, meaning the stimulation neither reduced hallucinations, nor improved negative symptoms, nor lifted mood or quality of life beyond what the placebo ritual itself achieved.

Safety, at least, was not in question. Serious adverse events unrelated to treatment occurred in five patients in the active group and seven in the sham group, a difference that was not statistically significant. The technique was well tolerated, and the trial confirmed that low-intensity electrical stimulation of this kind carries no meaningful physical risk when properly administered. But safety without efficacy is a hollow consolation for patients and clinicians, and the authors’ conclusion was blunt: tRNS did not show superiority over sham in reducing persistent symptoms of schizophrenia.

Why did a technique that showed promise in early studies fail so decisively here? The most instructive answer lies in the trial design itself. Small pilot studies and case reports are exquisitely vulnerable to placebo effects, publication bias, and regression to the mean, and psychiatric symptoms are especially susceptible to the powerful psychological ritual of receiving what feels like an active treatment. The sham group’s 13.2 percent response rate illustrates how much apparent improvement can arise from expectation, attention, and the natural fluctuation of symptoms alone. When these factors are rigorously controlled, as they were in STIM’Zo, the true effect of the intervention can shrink dramatically or vanish. The trial also raises deeper questions about mechanism: whether currents this weak, applied over the scalp and attenuated by skull and skin, can reach and meaningfully alter the deep and distributed circuits implicated in hallucinations remains uncertain. Some researchers argue that stimulation parameters, electrode positioning over regions such as the temporoparietal junction and dorsolateral prefrontal cortex, or the duration of treatment may need optimization, but the STIM’Zo data provide no support for the technique in its current form.

The implications extend well beyond tRNS. The result tempers enthusiasm for a wave of consumer and clinical enthusiasm around electrical brain stimulation for psychiatric conditions, and it underscores the necessity of large, triple-blind, sham-controlled trials before any brain stimulation protocol is adopted into routine care. It also offers a model of how the field should proceed: preregistered endpoints, multicenter recruitment, transparent funding, and honest reporting of negative results. For the patients who participated, and for the millions living with persistent voices and blunted lives, the trial did not deliver a new therapy, but it delivered something arguably just as valuable, a clear and trustworthy answer that redirects research toward approaches with a genuine chance of working. In science, knowing what does not work, and knowing it with confidence, is the first step toward finding what does.

Subject of Research: A triple-blind randomized trial testing transcranial random noise stimulation as an add-on treatment for persistent symptoms in schizophrenia.

Article Title: Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo)

Article References: Brunelin, J., Mondino, M., Plaze, M., Attal, J., Benoit, M., El-Hage, W., Galvao, F., Haesebaert, J., Jardri, R., Llorca, P. M., Magaud, L., Nathou, C., Szekely, D., Fakra, E., & Poulet, E. (2026). Low intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo). BMC Medicine. https://doi.org/10.1186/s12916-026-05227-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05227-7

Keywords: schizophrenia, tRNS, brain stimulation, auditory hallucinations, negative symptoms, placebo-controlled trial, BMC Medicine, psychiatry, tDCS, clinical trial, PANSS, noninvasive stimulation